Chagas disease is a neglected protozoan disease that affects more than eight million people in developing countries. Due to the limited number and toxicity profiles of therapies in current use, new drugs are urgently needed. In previous studies, we reported the isolation of two related antitrypanosomal neolignans from Nectandra leucantha (Lauraceae). In this work, a semi-synthetic library of twenty-three neolignan derivatives was prepared to explore synthetically accessible structure activity relationships (SAR) against Trypanosoma cruzi. Five compounds demonstrated activity against trypomastigotes (IC values from 8 to 64 μM) and eight showed activity against intracellular amastigotes (IC values from 7 to 16 μM). Eighteen derivatives demonstrated no mammalian cytotoxicity up to 200 μM. The phenolic acetate derivative of natural dehydrodieugenol B was effective against both parasite forms and eliminated 100% of amastigotes inside macrophages. This compound caused rapid and intense depolarization of the mitochondrial membrane potential, with decreased levels of intracellular reactive oxygen species being observed. Fluorescence assays demonstrated that this derivative affected neither the permeability nor the electric potential of the parasitic plasma membrane, an effect also corroborated by scanning electron microscopy studies. Structure-activity relationship studies (SARs) demonstrated that the presence of at least one allyl side chain on the biaryl ether core was important for antitrypanosomal activity, and that the free phenol is not essential. This set of neolignan derivatives represents a promising starting point for future Chagas disease drug discovery studies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2019.05.001DOI Listing

Publication Analysis

Top Keywords

trypanosoma cruzi
8
chagas disease
8
neolignan derivatives
8
activity
5
dehydrodieugenol derivatives
4
derivatives antiparasitic
4
antiparasitic agents
4
agents synthesis
4
synthesis biological
4
biological activity
4

Similar Publications

Eco-epidemiological Survey of Trypanosoma cruzi in Dogs from Mendoza, Argentina.

Ecohealth

January 2025

Laboratorio de Medicina y Endocrinología de la Fauna Silvestre, IMBECU, UNCuyo - CONICET, Av. Dr. Adrian Ruiz Leal s/n, Parque General San Martín, Mendoza, Argentina.

Urban domestic dog populations can provide important clues about the eco-epidemiological characteristics of Trypanosoma cruzi, the causative agent of Chagas disease (ChD). Given the limited data on ChD from the Metropolitan Area of Mendoza, Argentina, a seroprevalence survey of 327 dogs across an urban-rural gradient was conducted between April 2018 and May 2019. Seropositive cases were analyzed considering host, social, and environmental factors, subtypes (DTUs), and bloodstream parasite load.

View Article and Find Full Text PDF

Background: Determining esophageal and colon involvement in patients with Chagas disease occurs through invasive and uncomfortable examinations, which in most cases are not performed. The objective of this study was to assess the involvement of anti-M2-pyruvate kinase (M2-PK) autoantibodies in the development of digestive alterations and/or in the diagnosis of the digestive form of human Chagas disease.

Methods: The total IgG and isotype (IgG1, IgG2, IgG3, IgG4) production was quantified using the antigen of Trypanosoma cruzi and the human M2-PK recombinant protein via the ELISA technique.

View Article and Find Full Text PDF

Background: Trypanosoma cruzi is a protozoan parasite which causes Chagas disease. Mother-to-child transmission is the main route of transmission in vector-free areas. Congenital Chagas disease refers specifically to cases arising from this route of transmission.

View Article and Find Full Text PDF

Expression Analysis of Thirteen Genes in Response to Nifurtimox and Benznidazole in Mexican Isolates of Trypanosoma cruzi by Digital PCR.

Acta Parasitol

January 2025

Edificio D, Facultad de Ciencias Químicas, LADISER Inmunología y Biología Molecular, Universidad Veracruzana, Orizaba, Veracruz, México.

Despite being the most relevant and critical option for managing Chagas disease, pharmacological therapy is currently limited by the availability of only two drugs, benznidazole and nifurtimox. Their effectiveness is further restricted in the chronic phase of the infection, as they induce severe side effects and require prolonged treatment. Additionally, the use of these drugs can lead to the emergence of substantial resistance problems, compounded by the potential natural resistance of some parasite isolates.

View Article and Find Full Text PDF

Chagas disease is a neglected tropical disease caused by Trypanosoma cruzi with clinical presentations ranging from asymptomatic to cardiac and/or gastrointestinal complications. The mechanisms of pathogenesis are still poorly understood, but T. cruzi strain diversity may be associated with disease progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!